Helicobacter pylori infection and gastric atrophy:: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia

被引:262
作者
Ye, WM
Held, M
Lagergren, J
Engstrand, L
Blot, WJ
McLaughlin, JK
Nyrén, O
机构
[1] Vanderbilt Univ, Dept Med, Nashville, TN USA
[2] Swedish Inst Infect Dis Control, Stockholm, Sweden
[3] Karolinska Hosp, Dept Surg, S-10401 Stockholm, Sweden
[4] Int Epidemiol Inst, Rockville, MD USA
[5] Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden
[6] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2004年 / 96卷 / 05期
关键词
D O I
10.1093/jnci/djh057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: An inverse association between Helicobacter pylori infection and esophageal adenocarcinoma has been reported that may be attributed to reduced acidity from inducing atrophic gastritis and from producing ammonia. We examined associations between H. pylori infection, gastric atrophy, and the risk of esophageal adenocarcinoma, esophageal squamous-cell carcinoma, and gastric cardia adenocarcinoma in a large population-based case-control study in Sweden. Methods: Self-reported data were obtained during interviews, and serum was collected from 97 patients with incident esophageal adenocarcinoma, 85 patients with incident esophageal squamous-cell carcinoma, 133 patients with incident gastric cardia adenocarcinoma, and 499 randomly selected control subjects. Serum antibodies against whole H. pylori cell-surface antigens (HP-CSAs) and cytotoxin-associated gene A (CagA) antigens were assessed by an IgG enzyme-linked immunosorbent assay and immunoblotting, respectively. Gastric atrophy was assessed by serum levels of pepsinogen I. Multivariable logistic regression with adjustment for potential confounding factors was used to evaluate associations. Results: H. pylori infection, assayed by HP-CSA or CagA antibodies, was statistically significantly associated with a reduced risk for esophageal adenocarcinoma (for HP-CSA antibodies, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2 to 0.6; for CagA antibodies, OR = 0.5, 95% CI = 0.3 to 0.8; for both, OR = 0.2, 95% CI = 0.1 to 0.5). Gastric atrophy was not associated with the risk for esophageal adenocarcinoma (OR = 1.1, 95% CI = 0.5 to 2.5). Serum CagA antibodies and atrophy were associated with an increased risk for esophageal squamous-cell carcinoma (OR = 2.1, 95% CI = 1.1 4.0, and OR = 4.3, 95% CI = 1.9 to 9.6, respectively). risk of gastric cardia adenocarcinoma was not with H. pylori infection. However, gastric atrophy was associated with an increased risk for gastric cardia noma (OR = 4.5, 95% CI = 2.5 to 7.8). Conclusions: Infection with H. pylori may reduce the risk of adenocarcinoma, but it is unlikely to do so by reduced acidity. Gastric atrophy and infection with positive strains of H. pylori may increase the risk for ageal squamous-cell carcinoma.
引用
收藏
页码:388 / 396
页数:9
相关论文
共 50 条
[2]   Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease [J].
Befrits, R ;
Sjöstedt, S ;
Ödman, B ;
Sörngård, H ;
Lindberg, G .
HELICOBACTER, 2000, 5 (04) :202-205
[3]   Hypothesis:: The changing relationships of Helicobacter pylori and humans:: Implications for health and disease [J].
Blaser, MJ .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (06) :1523-1530
[4]   RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[5]   Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study [J].
Brenner, H ;
Rothenbacher, D ;
Bode, G ;
Adler, G .
BRITISH MEDICAL JOURNAL, 1997, 315 (7121) :1489-1492
[6]  
Bytzer P, 2000, SCAND J GASTROENTERO, V35, P1023, DOI 10.1080/003655200451135
[7]  
Chow WH, 1998, CANCER RES, V58, P588
[8]  
Craddock V M, 1992, Eur J Cancer Prev, V1, P89, DOI 10.1097/00008469-199202000-00002
[9]  
Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO
[10]  
2-U